Key clinical point: An international survey provides new insights into how COVID-19 has affected, and may continue to affect, the field of oncology.
Major finding: About 82% of oncologists surveyed said they were likely to continue the use of telemedicine in the future, but 45% said virtual international conferences are not an acceptable alternative to live conferences.
Study details: A survey of 109 oncologists in 18 countries, with answers recorded between June 17 and July 14, 2020.
Disclosures: The research was funded by Fondation Léon Fredericq. Dr. Jerusalem disclosed relationships with Novartis, Roche, Lilly, Pfizer, Amgen, Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo, AbbVie, MedImmune, and Merck.
Jerusalem G et al. ESMO 2020, .